Compare Stocks → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:AYRWFNASDAQ:CDXCNASDAQ:MNMDOTCMKTS:MRMD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYRWFAyr Wellness$2.31-7.2%$2.28$0.66▼$4.09$178.49M2.63342,353 shs119,790 shsCDXCChromaDex$3.38-0.3%$2.85$1.25▼$4.65$254.55M1.99263,009 shs7,996 shsMNMDMind Medicine (MindMed)$8.40-1.4%$8.39$2.41▼$12.22$590.27M2.811.88 million shs41,921 shsMRMDMariMed$0.27+3.4%$0.26$0.20▼$0.55$100.24M2.85273,656 shs126,577 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYRWFAyr Wellness-7.23%-6.48%+2.21%-29.36%+242.37%CDXCChromaDex-0.29%-10.55%-11.72%+121.57%+156.82%MNMDMind Medicine (MindMed)+0.71%-4.38%-13.59%+130.89%+134.71%MRMDMariMed+3.93%-3.36%+2.53%-20.95%-30.13%What is the 72-Hour Profit Surge? (Ad)One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYRWFAyr WellnessN/AN/AN/AN/AN/AN/AN/AN/ACDXCChromaDex3.5002 of 5 stars3.52.00.04.11.10.80.6MNMDMind Medicine (MindMed)2.1551 of 5 stars3.53.00.00.02.50.80.6MRMDMariMedN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYRWFAyr Wellness2.50Moderate BuyN/AN/ACDXCChromaDex3.00Buy$5.8773.57% UpsideMNMDMind Medicine (MindMed)3.00Buy$25.20200.00% UpsideMRMDMariMedN/AN/AN/AN/ACurrent Analyst RatingsLatest MRMD, CDXC, MNMD, and AYRWF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024MNMDMind Medicine (MindMed)Leerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/15/2024MNMDMind Medicine (MindMed)SVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.004/9/2024CDXCChromaDexRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.25 ➝ $6.003/14/2024MNMDMind Medicine (MindMed)HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.003/1/2024MNMDMind Medicine (MindMed)HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.002/29/2024MNMDMind Medicine (MindMed)Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$14.00 ➝ $15.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYRWFAyr Wellness$463.63M0.38$0.05 per share45.93$7.39 per share0.31CDXCChromaDex$83.57M3.05N/AN/A$0.38 per share8.89MNMDMind Medicine (MindMed)N/AN/AN/AN/A$1.90 per shareN/AMRMDMariMed$148.60M0.67$0.03 per share9.00$0.19 per share1.41Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYRWFAyr Wellness-$272.43M-$3.81N/A∞N/A-58.68%-14.13%-5.78%5/16/2024 (Estimated)CDXCChromaDex-$4.94M-$0.07N/A56.33N/A-5.91%-17.81%-9.17%5/8/2024 (Confirmed)MNMDMind Medicine (MindMed)-$95.73M-$2.45N/AN/AN/AN/A-89.72%-65.33%5/2/2024 (Estimated)MRMDMariMed-$16.03M-$0.04N/A∞N/A-10.79%-1.84%-0.72%N/ALatest MRMD, CDXC, MNMD, and AYRWF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/ACDXCChromaDex-$0.03N/A+$0.03N/AN/AN/A 3/13/2024Q4 2023AYRWFAyr Wellness-$0.26-$0.36-$0.10-$0.35$114.95 million$114.84 million2/28/2024Q4 2023MNMDMind Medicine (MindMed)-$0.48-$0.59-$0.11-$0.59N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYRWFAyr WellnessN/AN/AN/AN/AN/ACDXCChromaDexN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/AMRMDMariMedN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYRWFAyr Wellness0.750.960.43CDXCChromaDexN/A2.401.70MNMDMind Medicine (MindMed)0.183.223.22MRMDMariMed0.971.670.85OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYRWFAyr Wellness0.91%CDXCChromaDex15.41%MNMDMind Medicine (MindMed)27.91%MRMDMariMed0.18%Insider OwnershipCompanyInsider OwnershipAYRWFAyr Wellness8.10%CDXCChromaDex10.57%MNMDMind Medicine (MindMed)2.11%MRMDMariMed20.55%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAYRWFAyr Wellness2,30077.27 million71.01 millionNot OptionableCDXCChromaDex10675.31 million67.35 millionOptionableMNMDMind Medicine (MindMed)5770.27 million68.79 millionOptionableMRMDMariMed643375.13 million298.04 millionNot OptionableMRMD, CDXC, MNMD, and AYRWF HeadlinesSourceHeadlineCannabis Investors Share 'Chips Make Chunks' Wisdom For Business Expansion At Benzinga Conferencemsn.com - April 21 at 3:24 PM'A F—ed-Up Situation,' Says MariMed CCO About How State Regulations Complicate Cannabis Edibles Strategybenzinga.com - April 17 at 9:16 PMCritical Review: MariMed (OTCMKTS:MRMD) versus Cronos Group (NASDAQ:CRON)americanbankingnews.com - April 16 at 4:24 AMMariMed Closes Acquisition of Thrive Dispensary in Casey, The Company's Fifth Illinois Dispensaryuk.investing.com - April 13 at 9:31 PM3 Marijuana Stocks To Add To Your Watchlist This Weekmarijuanastocks.com - April 13 at 9:00 AMMariMed Is On A Roll: Partners With Two Iconic Music Venues In Boston, Acquires Another Illinois Cannabis Dispensarymsn.com - April 11 at 4:07 PMMariMed Closes Acquisition of Thrive Dispensary in Casey, The Company’s Fifth Illinois Dispensaryfinance.yahoo.com - April 11 at 9:25 AMMariMed Closes Acquisition of Thrive Dispensary in Casey, The Company’s Fifth Illinois Dispensaryfinance.yahoo.com - April 11 at 9:25 AMMariMed Closes Acquisition of Thrive Dispensary in Casey, The Company's Fifth Illinois Dispensaryglobenewswire.com - April 11 at 7:30 AMMass. cannabis firm sponsors MGM Music Hall, House of Bluesbizjournals.com - April 10 at 2:09 PMMariMed Partners with Iconic Boston Music Venuesglobenewswire.com - April 10 at 7:30 AMMariMed Partners with Iconic Boston Music Venuesglobenewswire.com - April 10 at 7:30 AMMariMed Inc.: MariMed Closes Acquisition of Second Maryland Dispensaryfinanznachrichten.de - April 9 at 12:20 PMMariMed Closes Acquisition of Second Maryland Dispensaryglobenewswire.com - April 9 at 7:30 AMMariMed Announces First Quarter 2024 Earnings Dateglobenewswire.com - April 8 at 7:30 AM'Unsexy' Alternative, Operating Within Constraints, Consistency & Love: 3 Experts On Making Cannabis Businesses Self-Sustainablemsn.com - March 27 at 8:06 PMA Bigger Dispensary Opens in the Town of “Big Things” as MariMed Opens Larger, Permanent Thrive Dispensary in Casey, Illinoisglobenewswire.com - March 12 at 7:30 AMMariMed Inc. (MRMD) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 9 at 1:17 PMMariMed Inc. (PNK:MRMD) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 8 at 8:27 PMMariMed Inc.: MariMed Reports Fourth Quarter and Full Year 2023 Earningsfinanznachrichten.de - March 8 at 12:01 AMMariMed Reports 'Another Year Of Strong Operational And Financial Performance' And More To Come In 2024msn.com - March 7 at 12:46 AMMRMD Stock Earnings: MariMed Beats Revenue for Q4 2023investorplace.com - March 7 at 12:02 AMMariMed's Earnings: A Previewbenzinga.com - March 6 at 7:46 PMMariMed Reports Fourth Quarter and Full Year 2023 Earningsglobenewswire.com - March 6 at 5:01 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyr WellnessOTCMKTS:AYRWFAyr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.ChromaDexNASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Mind Medicine (MindMed)NASDAQ:MNMDMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.MariMedOTCMKTS:MRMDMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.